Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.
Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, Röth A, Piatek C, Ogawa M, Yu J, Patel AS, Patel Y, Notaro R, Usuki K, Kulagin A, Gualandro S, Füreder W, Peffault de Latour R, Szer J, Lee JW.
Kulasekararaj A, et al. Among authors: lee jw.
Ann Hematol. 2025 Jan 22. doi: 10.1007/s00277-025-06193-5. Online ahead of print.
Ann Hematol. 2025.
PMID: 39841198